Breast implants of the US pharmaceutical giant Allergan, often marketed under the brand name Natrelle, are being recalled worldwide due to a cancer risk associated with them. Patients who have implants from the manufacturer should definitely get more information about this.
The US pharmaceutical company Allergan, which was taken over by its competitor Abbvie at the beginning of the year, has to launch a worldwide recall campaign for breast implants. The US Food and Drug Administration (FDA) has asked the company to voluntarily recall some of the company’s implant products.
Some Allergan breast implants pose a cancer risk
The FDA commented that it took significant action to protect women from breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) by requesting that Allergan, the manufacturer of a specific type of textured implant, recall specific models of its textured breast implants from the U.S. market due to the risk of BIA-ALCL.«
A voluntary recall, but also a serious situation
Apparently, the matter is more urgent than this official language suggests. Amy Abernethy is an employee of the FDA and says that a manufacturer’s implant »a specific manufacturer’s product appeared to be directly linked to significant patient harm, including death.«
The company, which suffered a loss of over $5 billion in 2018, is acting quickly and resolutely. All textured BIOCELL breast implants are recalled worldwide. This includes the following Natrelle implants: Natrelle Saline-Filled, Natrelle Silicone-Filled, Natrelle Inspira Silicone-Filled and Natrelle 410 Highly Cohesive Anatomically Shaped Silicone-Filled.
Further information can be found here. To be on the safe side, affected patients in from all parts of the world should consult their physicians.